Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child

Somasundaram Jayabose, Julie Dunbar, Theodore S. Nowicki, Oya Tugal, Mehmet Fevzi Ozkaynak, Claudio Sandoval

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Our patient first developed thrombotic thrombocytopenic purpura (TTP) at age 10 years with an initial platelet count of 10,000/μL. She achieved remission with plasmapheresis (PE), but suffered 2 relapses in the next 2 years, each approximately 1 year from PE, with ADAMTS13 levels of <5%. Early in her third remission, with vincristine (weekly ×-4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99% in 24 weeks, but decreased to <4% in the next 38 weeks. After 4 weekly doses of rituximab (375 mg/m2), her ADAMTS13 level reached 101% in 9 weeks and has remained consistently above 97% on bimonthly monitoring for more than a year. She remains in continuous clinical and hematologic remission with an ADAMTS13 level of 108% at 60 weeks from rituximab therapy and 124 weeks from her second relapse. This case report suggests that monitoring ADAMTS13 level at regular intervals in recurrent TTP may help us identify patients at risk for further relapse; and such a relapse may be prevented, or at least delayed with timely rituximab therapy, thus reducing morbidity from relapsed TTP and its treatment.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalPediatric Hematology and Oncology
Volume28
Issue number2
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Thrombotic Thrombocytopenic Purpura
Recurrence
Plasmapheresis
Vincristine
Therapeutics
Prednisone
Platelet Count
Morbidity
Rituximab

Keywords

  • refractory
  • relapsing
  • rituximab
  • thrombotic thrombocytopenic purpura
  • TTP

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child. / Jayabose, Somasundaram; Dunbar, Julie; Nowicki, Theodore S.; Tugal, Oya; Ozkaynak, Mehmet Fevzi; Sandoval, Claudio.

In: Pediatric Hematology and Oncology, Vol. 28, No. 2, 03.2011, p. 167-172.

Research output: Contribution to journalArticle

Jayabose, Somasundaram ; Dunbar, Julie ; Nowicki, Theodore S. ; Tugal, Oya ; Ozkaynak, Mehmet Fevzi ; Sandoval, Claudio. / Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child. In: Pediatric Hematology and Oncology. 2011 ; Vol. 28, No. 2. pp. 167-172.
@article{96c75a2e6df34048bdc3e321d8e79888,
title = "Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child",
abstract = "Our patient first developed thrombotic thrombocytopenic purpura (TTP) at age 10 years with an initial platelet count of 10,000/μL. She achieved remission with plasmapheresis (PE), but suffered 2 relapses in the next 2 years, each approximately 1 year from PE, with ADAMTS13 levels of <5{\%}. Early in her third remission, with vincristine (weekly ×-4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99{\%} in 24 weeks, but decreased to <4{\%} in the next 38 weeks. After 4 weekly doses of rituximab (375 mg/m2), her ADAMTS13 level reached 101{\%} in 9 weeks and has remained consistently above 97{\%} on bimonthly monitoring for more than a year. She remains in continuous clinical and hematologic remission with an ADAMTS13 level of 108{\%} at 60 weeks from rituximab therapy and 124 weeks from her second relapse. This case report suggests that monitoring ADAMTS13 level at regular intervals in recurrent TTP may help us identify patients at risk for further relapse; and such a relapse may be prevented, or at least delayed with timely rituximab therapy, thus reducing morbidity from relapsed TTP and its treatment.",
keywords = "refractory, relapsing, rituximab, thrombotic thrombocytopenic purpura, TTP",
author = "Somasundaram Jayabose and Julie Dunbar and Nowicki, {Theodore S.} and Oya Tugal and Ozkaynak, {Mehmet Fevzi} and Claudio Sandoval",
year = "2011",
month = "3",
doi = "10.3109/08880011003739414",
language = "English (US)",
volume = "28",
pages = "167--172",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Rituximab therapy to prevent relapse in chronic relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a child

AU - Jayabose, Somasundaram

AU - Dunbar, Julie

AU - Nowicki, Theodore S.

AU - Tugal, Oya

AU - Ozkaynak, Mehmet Fevzi

AU - Sandoval, Claudio

PY - 2011/3

Y1 - 2011/3

N2 - Our patient first developed thrombotic thrombocytopenic purpura (TTP) at age 10 years with an initial platelet count of 10,000/μL. She achieved remission with plasmapheresis (PE), but suffered 2 relapses in the next 2 years, each approximately 1 year from PE, with ADAMTS13 levels of <5%. Early in her third remission, with vincristine (weekly ×-4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99% in 24 weeks, but decreased to <4% in the next 38 weeks. After 4 weekly doses of rituximab (375 mg/m2), her ADAMTS13 level reached 101% in 9 weeks and has remained consistently above 97% on bimonthly monitoring for more than a year. She remains in continuous clinical and hematologic remission with an ADAMTS13 level of 108% at 60 weeks from rituximab therapy and 124 weeks from her second relapse. This case report suggests that monitoring ADAMTS13 level at regular intervals in recurrent TTP may help us identify patients at risk for further relapse; and such a relapse may be prevented, or at least delayed with timely rituximab therapy, thus reducing morbidity from relapsed TTP and its treatment.

AB - Our patient first developed thrombotic thrombocytopenic purpura (TTP) at age 10 years with an initial platelet count of 10,000/μL. She achieved remission with plasmapheresis (PE), but suffered 2 relapses in the next 2 years, each approximately 1 year from PE, with ADAMTS13 levels of <5%. Early in her third remission, with vincristine (weekly ×-4 doses) and prednisone (for 2 weeks) her ADAMTS13 increased to 99% in 24 weeks, but decreased to <4% in the next 38 weeks. After 4 weekly doses of rituximab (375 mg/m2), her ADAMTS13 level reached 101% in 9 weeks and has remained consistently above 97% on bimonthly monitoring for more than a year. She remains in continuous clinical and hematologic remission with an ADAMTS13 level of 108% at 60 weeks from rituximab therapy and 124 weeks from her second relapse. This case report suggests that monitoring ADAMTS13 level at regular intervals in recurrent TTP may help us identify patients at risk for further relapse; and such a relapse may be prevented, or at least delayed with timely rituximab therapy, thus reducing morbidity from relapsed TTP and its treatment.

KW - refractory

KW - relapsing

KW - rituximab

KW - thrombotic thrombocytopenic purpura

KW - TTP

UR - http://www.scopus.com/inward/record.url?scp=79751519396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751519396&partnerID=8YFLogxK

U2 - 10.3109/08880011003739414

DO - 10.3109/08880011003739414

M3 - Article

C2 - 20469972

AN - SCOPUS:79751519396

VL - 28

SP - 167

EP - 172

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 2

ER -